Bioanalysis of Small Molecules & Generics

Kymos Group specializes in world-class bioanalysis of small molecules, offering a comprehensive range of services from fast in vivo and in vitro ADMET screenings to pre-clinical toxicokinetics, bioavailability and pharmacokinetic studies, drug-drug interaction studies, and clinical trials including first-in-man and dose escalation studies.

Our bioanalysis experts are experienced in comprehensively managing pre-clinical and clinical bioanalysis of small molecules from phases I to IV and bioequivalences for generics. We are a GLP-certified and GCP-compliant multinational CRO with broad experience catering to various client profiles, including:

• Large generics companies seeking full bioequivalence studies.

• Small biotech innovators conducting basic research and development (R&D).

• Animal health firms requiring residue depletion studies.